Cancer Nanomedicine: from bench to bedside
Institute of Oncology Research
Start date: 13 March 2023
End date: 14 March 2023
Training school organized by Nano2Clinic COST Action CA17140
Preclinical and clinical studies of cancer nanomedicine – state of the art and future perspectives
The field of nanomedicine has seen substantial progress in the last few years. Many products have reached the market and are under clinical investigation, and many more nanomedicine-based therapeutics are in development and undergoing preclinical evaluation. Nanomedicine may revolutionize cancer treatment, moving it toward the era of precision cancer medicine. Improving methods and approaches for preclinical and clinical investigation is a strategic need for the nanomedicine field, particularly for oncological applications. The 2-day Training School, organized by WG3 and WG4 of the Nano2Clinic COST Action CA17140, will feature presentations and practical sessions on the methodological approaches and technologies available for advanced preclinical and clinical studies of cancer nanomedicines and an overview of the stakeholders in the field at academic and industrial levels. The intent is to allow young scientists to interact with expert researchers and discuss various techniques and applications, from the biological and functional characterization of nanomaterials to anticancer efficacy studies in cell cultures and in vivo models and the planning of early-phase clinical trials.